Jagsonpal Pharmaceuticals Limited has informed the Exchange about Investor Presentation
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals reported a strong Q1FY26 with revenue up 23.1% YoY to ₹756 Mn, driven by growth in its key brands. Operating EBITDA rose 24.1% to ₹157 Mn with margins expanding to 20.8%, while net profit more than doubled to ₹108 Mn, pushing PAT margin to 14.3% (up 562 bps). The company is debt-free with a cash balance of ₹1,609 Mn, after adding ₹153 Mn of free cash in the quarter. Management stated it will use this cash to pursue a 'strategically suitable inorganic opportunity' and laid out a multi-year growth roadmap. Key therapy rankings improved, including climbing to #7 in the Gynae CVM segment. The company launched an updated investor presentation to correct an inadvertent error on pages 10 and 11 of the original document filed the same day.
Positive for shareholders — strong topline growth, margin expansion, and a doubling of PAT signal healthy business momentum. The large cash pile and management's hint at an inorganic acquisition could act as a near-term catalyst, though execution risk remains. Multi-year guidance of 23%+ revenue growth beyond FY26 sets an ambitious tone for the stock.